The National Cancer Institute's (NCI) Clinical Proteomic Technologies for Cancer (CPTC) initiative at the National Institutes of Health has entered into a memorandum of understanding (MOU) with the Korea...
COVID-19 is an emerging, rapidly evolving siituation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
All | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010
Displaying 1 - 6 of 6The National Cancer Institute's (NCI) Clinical Proteomic Technologies for Cancer (CPTC) initiative at the National Institutes of Health has entered into a memorandum of understanding (MOU) with the Korea...
The National Cancer Institute, through its Clinical Proteomic Technologies for Cancer (CPTC) initiative has entered into a memorandum of understanding with the American Association for Clinical Chemistry (AACC) to join...
In the special December issue of Proteomics Clinical Applications , two articles focus directly on scientific outputs from CPTC. A Viewpoint article, authored by Participants of a Wellcome Trust/EBI meeting and retreat (...
An NCI-FDA Interagency Oncology Task Force (IOTF) Molecular Diagnostics Workshop was held on October 30, 2008 in Cambridge, MA, to discuss requirements for analytical validation of protein-based multiplex technologies in the context of its intended use. This workshop developed through NCI's Clinical...
Q1. What are some of the key goals for AACC and its members in 2011?
The yeast protein extract (RM8323) developed by National Institute of Standards and Technology (NIST) under the auspices of NCI's CPTC initiative is currently available to the public at https://www-s.nist.gov/srmors/view_detail.cfm?srm=...